| D20 | The impact of the COVID-19 pandemic on provision of HIV care: perspectives of HIV-dedicated healthcare workers in East Africa | On-demand oral abstract session | Adaptations of HIV treatment services during COVID-19 |
| D20 | Evaluating the integration of telehealth in same-day antiretroviral initiation service during COVID-19 in Bangkok, Thailand | On-demand oral abstract session | Adaptations of HIV treatment services during COVID-19 |
| D20 | Successful implementation of telemedicine and pharmacy enhanced HIV services as response to COVID-19 quarantine among health insured patients in Argentina | On-demand oral abstract session | Adaptations of HIV treatment services during COVID-19 |
| D10 | CUSTOMIZE: overall results from a hybrid III implementation-effectiveness study examining implementation of cabotegravir and rilpivirine long-acting injectable for HIV treatment in US healthcare settings; final patient and provider data | On-demand oral abstract session | Operational challenges in implementing HIV services |
| D18 | Patterns of patient-provider communications in public HIV clinics in Zambia: a latent class analysis using RIAS | On-demand oral abstract session | Indicators of quality of care |
| A43 | SARS-Cov-2 immunity in COVID-19 convalescent individuals living with HIV: bulk immune profiling and SARS-CoV-2 specific humoral and cellular immune responses | Oral abstract session with live Q&A | Co-infection: SARS-Co-V2 |
| A43 | SARS-CoV-2-seronegative subjects target CTL epitopes in the SARS-CoV-2 nucleoprotein cross-reactive to common cold coronaviruses | Oral abstract session with live Q&A | Co-infection: SARS-Co-V2 |
| A41 | Viral hepatitis cascade of care among adults living with HIV in Asia-Pacific | Oral abstract session with live Q&A | Co-infection: Viral hepatitis |
| A18 | In-vivo imaging using anti-ENV probes in SIV infected monkeys: a reproducibility study | Oral abstract session with live Q&A | Cellular and tissue reservoirs of HIV/SIV |
| A22 | Dual IL-10 and PD-1 blockade in SIVmac239 infected macaques promotes sustained virologic control in absence of ART | Oral abstract session with live Q&A | Immunotherapy: Immune-Modifying Agents |